Talk:Roflumilast

Rofmil
Two editors (which appear to be socks by their behavior, and ) have added information about "Rofmil" to the article, sourced to this website, which says the drug is sold under that name by Intas. But if you go to the Intas products pages, it is not listed there, and if you do a google search on rofmil+Roflumilast you get only 4 hits - 3 to that website and one to our article. This is not reliably sourced per WP:MEDRS nor even WP:RS, so per WP:VERIFY I took it out. We need a reliable source to include this. Jytdog (talk) 12:42, 12 December 2014 (UTC)


 * Please note roflumilast is a life saving medicine which is now available in India under the trade name of Rofmil, same is now listed on intas pharma website (www.intaspharma.com). It is imperative to announce the launch of this molecule in India as COPD is widely prevalent amongst Indian population. — Preceding unsigned comment added by Newcomer1234 (talk • contribs) 10:53, 19 December 2014‎ (UTC)


 * Please respond to the sourcing issues raised above. I am again removing the material. Your note above makes it clear that you are here for promotional reasons which is against policy.    If you add back again without dealing with the sourcing issues (see the policy WP:VERIFY, you will lose your editing privileges.  If you provide some links to reliable sources that the drug is available in India here, I can help you add content to the article.  But the way you are doing it is not OK.  A link to the main Intas website is not ok.Jytdog (talk) 12:11, 19 December 2014 (UTC)

Suggested Edits
Update the trade names for roflumilast to Dalaresp (oral, US trade name for COPD), Daxas (oral, EMA trade name for Europe for COPD) and Zoryve (topical cream, US trade name indication plaque psoriasis). Sources https://www.ema.europa.eu/en/medicines/human/EPAR/daxas, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215985s000lbl.pdf

Add details for topical roflumilast cream (Zoryve). Source: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215985s000lbl.pdf

Date of FDA approval: July 29, 2022 Indication:  topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older. The most common side effects of ZORYVE include: diarrhea headache trouble sleeping nausea application site pain upper respiratory tract infections urinary tract infections (UTIs) 47.156.15.130 (talk) 18:01, 30 August 2023 (UTC)